{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:16:25Z","timestamp":1762607785885,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40266-019-00737-x","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T04:18:08Z","timestamp":1583727488000},"page":"281-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5466-9971","authenticated-orcid":false,"given":"Dheeraj","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Milentijevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Simon","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"issue":"12","key":"737_CR1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013492.","journal-title":"Circulation"},{"key":"737_CR2","unstructured":"Center for Disease Control and Prevention. Atrial fibrillation fact sheet. 2017. https:\/\/www.cdc.gov\/dhdsp\/data_statistics\/fact_sheets\/fs_atrial_fibrillation.htm. Accessed 23 Jan 2019."},{"key":"737_CR3","unstructured":"National Institute of Neurological Disorders and Stroke. Atrial fibrillation and stroke information page. 2018. https:\/\/www.ninds.nih.gov\/Disorders\/All-Disorders\/Atrial-Fibrillation-and-Stroke-Information-Page. Accessed 11 Mar 2019."},{"issue":"4","key":"737_CR4","first-page":"331","volume":"162","author":"GD Stettin","year":"1995","unstructured":"Stettin GD. Treatment of nonvalvular atrial fibrillation. West J Med. 1995;162(4):331\u20139.","journal-title":"West J Med"},{"issue":"9","key":"737_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1212\/WNL.0b013e3182a2cc15","volume":"81","author":"ER McGrath","year":"2013","unstructured":"McGrath ER, Kapral MK, Fang J, Eikelboom JW, Conghaile A, Canavan M, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013;81(9):825\u201332.","journal-title":"Neurology."},{"issue":"1","key":"737_CR6","first-page":"104","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;74(1):104\u201332.","journal-title":"Circulation"},{"key":"737_CR7","first-page":"15","volume":"4","author":"M Alcusky","year":"2018","unstructured":"Alcusky M, Lapane KL. Treatment of atrial fibrillation in nursing homes: a place for direct acting oral anticoagulants? J Nurs Home Res Sci. 2018;4:15\u20139.","journal-title":"J Nurs Home Res Sci."},{"issue":"9","key":"737_CR8","doi-asserted-by":"publisher","first-page":"e012023","DOI":"10.1161\/JAHA.119.012023","volume":"8","author":"M Alcusky","year":"2019","unstructured":"Alcusky M, McManus DD, Hume AL, Fisher M, Tjia J, Lapane KL. Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016. J Am Heart Assoc. 2019;8(9):e012023.","journal-title":"J Am Heart Assoc."},{"key":"737_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/CIA.S159373","volume":"13","author":"N Ekerstad","year":"2018","unstructured":"Ekerstad N, Karlsson T, Soderqvist S, Karlson BW. Hospitalized frail elderly patients\u2014atrial fibrillation, anticoagulation and 12\u00a0months\u2019 outcomes. Clin Interv Aging. 2018;13:749\u201356.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"737_CR10","first-page":"179","volume":"14","author":"K Wasmer","year":"2017","unstructured":"Wasmer K, Eckardt L, Breithardt G. Predisposing factors for atrial fibrillation in the elderly. J Geriatr Cardiol. 2017;14(3):179\u201384.","journal-title":"J Geriatr Cardiol."},{"key":"737_CR11","unstructured":"National Heart Lung and Blood Institute. Atrial fibrillation. https:\/\/www.nhlbi.nih.gov\/health-topics\/atrial-fibrillation. Accessed 18 Jul 2018."},{"issue":"10","key":"737_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"key":"737_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijcard.2018.11.087","volume":"282","author":"J Salcedo","year":"2019","unstructured":"Salcedo J, Hay JW, Lam J. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. Int J Cardiol. 2019;282:53\u20138.","journal-title":"Int J Cardiol"},{"issue":"10","key":"737_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40273-013-0087-9","volume":"31","author":"J Kleintjens","year":"2013","unstructured":"Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909\u201318.","journal-title":"Pharmacoeconomics."},{"issue":"28","key":"737_CR15","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"23","key":"737_CR16","first-page":"e199","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199\u2013267.","journal-title":"Circulation"},{"issue":"6","key":"737_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.amjmed.2006.07.045","volume":"120","author":"JH Gurwitz","year":"2007","unstructured":"Gurwitz JH, Field TS, Radford MJ, Harrold LR, Becker R, Reed G, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007;120(6):539\u201344.","journal-title":"Am J Med"},{"key":"737_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12912-015-0058-x","volume":"14","author":"AA Patel","year":"2015","unstructured":"Patel AA, Nelson WW. Nurses\u2019 self-reported time estimation of anticoagulation therapy: a survey of warfarin management in long-term care. BMC Nurs. 2015;14:8.","journal-title":"BMC Nurs."},{"issue":"12","key":"737_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"22","key":"737_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"11","key":"737_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"key":"737_CR22","unstructured":"American Health Care Association. SNF Value-Based Purchasing (SNF VBP). https:\/\/www.ahcancal.org\/facility_operations\/Pages\/SNF-Value-Based-Purchasing.aspx. Accessed 2 Apr 2019."},{"key":"737_CR23","unstructured":"Castellucci M. Most skilled-nursing facilities penalized by CMS for readmission rates. 2018. https:\/\/www.modernhealthcare.com\/article\/20181128\/NEWS\/181129930\/most-skilled-nursing-facilities-penalized-by-cms-for-readmission-rates. Accessed 12 Jun 2019."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00737-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:54:24Z","timestamp":1615251264000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00737-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00737-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"9 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"V. Simon Mittal and Dheeraj Mahajan have no conflicts of interest to declare. Bingcao Wu, Ji Song, Dejan Milentijevic, and Veronica Ashton are full-time employees of Janssen Scientific Affairs, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by Janssen Scientific Affairs, LLC (Titusville, NJ, USA). Medical writing support was provided by Alaina Mitsch, PhD, of MedErgy (Yardley, PA, USA), and was funded by Janssen Scientific Affairs, LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}